Adriana M. Hung

Vanderbilt University Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Background African Americans are at increased risk for chronic kidney disease (CKD) in part due to Apolipoprotein L1 gene (APOL1) high-risk genotypes. Recently, a study from West Africa reported an association between monoallelic genotypes and risk of CKD and focal segmental glomerulosclerosis (FSGS). We here study the association of biallelic and monoallelic genotypes with CKD, proteinuria, and FSGS in participants in a hospital-based cohort in the Southeastern United States. Methods We conducted a case-control study of African Ancestry participants from the Vanderbilt University Medical Center Biobank (n=23, 857). The primary outcome was CKD defined as: persistent GFR 700 mg/g or albumin-to-creatinine ratio of >420 mg/g. Secondary outcomes were proteinuria and FSGS outcomes separately. The primary exposure was APOL1 monoallelic genotype (1 copy of a risk allele versus none). APOL1 biallelic genotypes was studied as a secondary exposure. Sequential logistic regression models were performed adjusting for potential confounders. Results Among 23,857 participants, 5,784 had CKD, 1,533 had proteinuria, and 80 had biopsy-proven FSGS, 44.5% had one risk allele (monoallelic) and 13.6% had two risk alleles (biallelic). Biallelic carriers had higher odds of CKD than those with one or no risk alleles (adjusted odds ratio ( aOR ), 1.72; 95% confidence interval [CI], 1.57-1.89), proteinuria aOR = 2.02 (95% CI, 1.77-2.31), and FSGS aOR = 17.48 (95%CI 10.53-29.02). Monoallelic carriers (G0/G1 or G0/G2) had a small increase in odds of CKD ( aOR = 1.08, 95% CI 1.00-1.16, p=0.04), which was driven by the G0/G2 genotype ( aOR = 1.11, 95% CI 1.01-1.23, p=0.03). Monoallelic carriers (G0/G1 or G0/G2) had higher odds of proteinuria ( aOR = 1.23; 95% CI, 1.09-1.39) and G0/G1 had higher odds of FSGS (14 cases) ( aOR = 2.83; 95% CI, 1.18-6.79). Conclusions In our study, monoallelic APOL1 genotypes were associated with 23% higher odds of proteinuria and 3-fold higher odds of FSGS for G0/G1. A modest increase odd for CKD of 8%, which may reflect CKD phenotypic heterogeneity. Our study supports the observations from a West Africa cohort in a US based cohort and adds the association of APOL1 monoallelic genotypes with proteinuria.

Year:

2025

Background Components of arterial stiffness (structural stiffness from aging and load-dependent stiffness from high blood pressure) are markers for cardiovascular disease risk. We evaluated relationships between polygenic risk scores (PRS) for blood pressure (BP) and arterial stiffness. Methods Participants (n=5942) are from the Multi-Ethnic Study of Atherosclerosis with measures of carotid ultrasound and genomic DNA. Pulse wave velocity (PWV) was calculated from carotid ultrasound representing total stiffness. Structural stiffness was calculated by adjusting PWV to a 120/80 mmHg blood pressure with participant-specific models. Load-dependent stiffness was the difference of total and structural stiffness. Blood pressure PRSs were previously derived from a genome-wide association study. Associations between BP PRSs and components of carotid arterial stiffness were assessed with multivariable-adjusted regression models. Mendelian Randomization (MR) was performed with two-stage least squares to 1) confirm that BP PRSs strongly predict MAP and 2) estimate the effect of MAP on arterial stiffness. Results Participants (n=5,942) were mean (standard deviation) age of 62.8 (10.3) years (52% female; 39% White, 25% African-American, 13% Asian, 23% Hispanic). Systolic BP (SBP) was 133.5 (20.5) mmHg, diastolic BP (DBP) was 74.27 (10.28) mmHg and pulse pressure (PP) was 59.22 (16.17) mmHg. Total carotid stiffness was associated with the SBP PRS ( β =0.10 +/-0.02, p=5.25E-08) and the DBP PRS ( β : 0.08 +/-0.02, p=7.26E-07) but not PP PRS ( β =0.04 +/-0.02, P=0.05). Load dependent carotid stiffness was associated with the SBP PRS β =0.09 +/-0.01, p=7.93*10 -30 ) the DBP PRS ( β =0.09 +/-0.01, p= 4.92*10 -34 ) and the PP PRS ( β =0.03 +/-0.01, p= 8.18* 10-5 ). Structural carotid stiffness was not associated with any BP PRSs. MR showed that SBP and DPB PRS strongly predict MAP (p<0.001) and each 1-mmHg increase in MAP raised load dependent stiffness by 0.0494 m/s (p<0.001). Conclusion There are key differences in the genetic underpinnings of the mechanistic components of arterial stiffness.

Year:

2025

Glucagon-like peptide-1 receptor agonists (GLP1RAs) are transformative therapies for diabetes and obesity, yet their long-term clinical effects are incompletely understood. To address this, we conducted a phenome-wide association study (PheWAS) to assess potential therapeutic and adverse effects of GLP1RAs using genetic drug proxies near the GLP1R locus. Fifteen variants associated with GLP1R expression in the Genotype-Tissue Expression (GTEx) project were tested against 1,204 phecodes in the Million Veteran Program (MVP, n = 464,626), with replication and meta-analysis within the UK Biobank (n = 449,349) and the Vanderbilt BioVU (n = 118,130). In the MVP, GLP1RA proxies showed expected metabolic benefits, including lower risk of type 2 diabetes (OR = 0.966, 95% CI [0.957-0.974], p = 4.55 × 10 −14 ] and obesity (OR = 0.978, 95% CI [0.969-0.986], p = 6.94×10 −7 ). Protective effects were also found for chronic venous insufficiency, obstructive sleep apnea, cancer of the esophagus, orthopnea, and diabetes complications (retinopathy, nephropathy, retinopathy). However, associations with mental health disorders were cohort-dependent (anxiety disorders in MVP OR = 1.02, 95% CI [1.012-1.0316], p = 1.07 × 10 −5 , BioVU OR = 0.960, 95% CI [0.938-0.981], p = 3.12 × 10 −4 ). The results reinforce the therapeutic promise of GLP1RAs for metabolic diseases while underscoring the need for cautious monitoring of potential mental health effects.

Year:

2025

Interpreting proteomic associations with chronic kidney disease (CKD) is challenging due to the disease’s clinical heterogeneity and complex overlap with systemic conditions. We present a framework that identifies causal circulating protein drivers of CKD and delineates their subtype- specific and systemic effects using electronic health record (EHR) data at biobank scale. Using proteome-wide Mendelian randomization, we instrumented cis-acting protein quantitative trait loci for 2,807 circulating proteins and tested them against detailed, EHR-based kidney function outcomes in 464,631 Million Veteran Program participants. Proteins were mapped to nine kidney disease subtypes defined by genome-wide association meta-analyses from the Million Veteran Program, UK Biobank, and FinnGen. Phenome-wide association studies across 1,020 traits distinguished renal versus extra-renal associations. This integrative strategy prioritizes 93 proteins with proteome-wide significance for kidney outcomes, demonstrates subtype-specific relevance, exposes systemic associations, and maps therapeutic targets to nominate candidates for drug development and repurposing.

Year:

2025

Significance Statement Rapid progression of CKD is associated with poor clinical outcomes. Most previous studies looking for genetic factors associated with low eGFR have used cross-sectional data. The authors conducted a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD, focusing on longitudinal data. They identified three loci (two of them novel) associated with longitudinal eGFR decline. In addition to the known UMOD/ PDILT locus, variants within BICC1 were associated with significant differences in longitudinal eGFR slope. Variants within HEATR4 also were associated with differences in eGFR decline, but only among Black/African American individuals without diabetes. These findings help characterize molecular mechanisms of eGFR decline in CKD and may inform new therapeutic approaches for progressive kidney disease. Background Rapid progression of CKD is associated with poor clinical outcomes. Despite extensive study of the genetics of cross-sectional eGFR, only a few loci associated with eGFR decline over time have been identified. Methods We performed a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD—defined by two outpatient eGFR measurements of <60 ml/min per 1.73 m 2 , obtained 90–365 days apart—from the Million Veteran Program and Vanderbilt University Medical Center's DNA biobank. The primary outcome was the annualized relative slope in outpatient eGFR. Analyses were stratified by ethnicity and diabetes status and meta-analyzed thereafter. Results In cross-ancestry meta-analysis, the strongest association was rs77924615, near UMOD / PDILT ; each copy of the G allele was associated with a 0.30%/yr faster eGFR decline ( P = 4.9×10 −27 ). We also observed an association within BICC1 (rs11592748), where every additional minor allele was associated with a 0.13%/yr slower eGFR decline ( P = 5.6×10 −9 ). Among participants without diabetes, the strongest association was the UMOD/PDILT variant rs36060036, associated with a 0.27%/yr faster eGFR decline per copy of the C allele ( P = 1.9×10 −17 ). Among Black participants, a significantly faster eGFR decline was associated with variant rs16996674 near APOL1 (R 2 =0.29 with the G1 high-risk genotype); among Black participants with diabetes, lead variant rs11624911 near HEATR4 also was associated with a significantly faster eGFR decline. We also nominally replicated loci with known associations with eGFR decline, near PRKAG2, FGF5, and C15ORF54. Conclusions Three loci were significantly associated with longitudinal eGFR change at genome-wide significance. These findings help characterize molecular mechanisms of eGFR decline and may contribute to the development of new therapeutic a

Year:

2023

Collaborators (5)

Adam D. Gepner

University of Wisconsin-Madison

UNITED STATES
View details

Cassianne Robinson‐Cohen

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Ayush Giri

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Talat Ikizler

Vanderbilt University Medical Center

UNITED STATES
View details

Lekki Wood

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details